INTRALINE® ONE is a hyaluronic acid (HA) dermal filler crafted for the enhancement of fine to medium lines and delicate facial areas. This refined formula uses medium-sized spherical HA particles at a concentration of 20 mg/mL, designed to blend naturally and smoothly for subtle rejuvenation.

Key Benefits
• Soft, natural volume enhancement in sensitive regions such as under the eyes and around the lips
• Spherification technology for smoother particle structure and improved integration into tissue
• Designed for specific areas: tear-troughs, perioral “smoker’s lines”, Cupid’s bow, lips definition, shallow nasolabial folds and marionette lines
• Minimal downtime — ideal for delicate skin zones

How It Works
By employing specially shaped HA particles, INTRALINE® ONE supports the dermal structure in mid-to-superficial dermal layers, filling hollows and smoothing transitions. The gel distributes evenly across the targeted area, providing subtle lift and contour while maintaining natural movement and expression.

Ideal Candidates
Adults experiencing early or moderate signs of volume loss or fine wrinkles, particularly in sensitive or high-movement areas. Candidates who desire refined enhancement rather than dramatic volumisation.

Common Treatment Areas Include:
• Tear-troughs (under-eye hollows)
• Perioral lines / “smoker’s lines”
• Cupid’s bow and lip-border enhancement
• Shallow nasolabial folds and marionette lines

Administration
Supplied in a sterile, single-use 1 mL pre-filled syringe with the appropriate needles. Injections are typically placed into the mid-dermis using a 27 G gauge needle or cannula, at the discretion of the practitioner. Results are visible immediately and may last up to approximately 9-12 months, depending on treatment area, patient metabolism, and after-care.

Possible Side Effects
Common temporary responses include redness, swelling, tenderness, mild bruising or firmness at the injection site. Rare allergic or inflammatory reactions may occur. Selection of a qualified medical professional and adherence to post-treatment care significantly reduces risks.